Physician profile

Michael D Lichter

Dermatology · Nashua, NH

NPI 1962572305

$53,478.80

in general payments reported to CMS, 2019-2025

23 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $45,819.85 2019-2022
Leo Pharma INC. $1,554.25 2019-2022
Amgen INC. $1,049.33 2020-2022
Janssen Biotech, INC. $1,044.18 2019-2022
Novartis Pharmaceuticals Corporation $867.67 2019-2022
Sun Pharmaceutical Industries INC. $436.46 2019-2022
Genzyme Corporation $415.58 2019-2022
Ucb, INC. $374.75 2019-2022
Sanofi-Aventis U.S. LLC $308.89 2019-2020
Lilly USA, LLC $298.15 2019-2022
Regeneron Healthcare Solutions, INC. $225.60 2019-2021
Incyte Corporation $208.48 2022
Genentech USA, INC. $166.48 2020-2022
Pfizer INC. $148.68 2019-2022
Vyne Pharmaceuticals INC. $106.98 2020-2021
Show all 23 companies
CompanyGeneral paymentsYearsTop products
Helsinn Therapeutics (U.S.), INC. $102.58 2019-2022
Celgene Corporation $89.47 2019
Janssen Scientific Affairs, LLC $89.05 2019
E.R. Squibb & Sons, L.L.C. $68.76 2022
Galderma Laboratories, L.P. $40.87 2021-2022
Mayne Pharma Commercial LLC $29.63 2019
Dermira, INC. $19.50 2019
Smith+Nephew, INC. $13.61 2021

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael D Lichter

$53,478.80

in general payments reported 2019-2025

Years
2019-2022
Top company
Abbvie INC.

https://glasscript.com/doctor/316291/michael-d-lichter

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.